Answers are grounded in this paper and cite their sources.
Introduction: Immunocompromised patients, especially those with cancer, face an elevated risk of developing inflamed and painful rashes between the skinfolds. These intertriginous conditions are not always easy to identify. Case Series: We report a case series of three neutropenic patients, two with acute myeloblastic leukemia (AML) and one with metastatic left invasive ductal carcinoma, presenting to the hospital dermatology consult team with intertriginous skin eruptions. The patients were diagnosed with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), ecthyma gangrenosum, and toxic erythema of chemotherapy. Treatment and management of these cases involved topical steroids, antibiotics, and chemotherapy dosing adjustment. Conclusion: This paper explores the various infectious, inflammatory, and other etiologies of intertriginous rashes in immunocompromised and neutropenic patients.
No takes yet. Share an insight, caveat, or question.
Weygand et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: